- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
- Idorsia takes steps to address short-term liquidity needs
- Idorsia thanks Guy Braunstein for his years of service as he retires
- US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration
- Idorsia and Viatris enter into a significant global research and development collaboration
- Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
- New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
- Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt – Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert
- Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
More ▼
Key statistics
On Wednesday, Idorsia Ltd (IDIA:SWX) closed at 1.82, 40.65% above the 52 week low of 1.29 set on Jan 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.00 |
---|---|
High | 2.05 |
Low | 1.65 |
Bid | -- |
Offer | -- |
Previous close | 1.82 |
Average volume | 974.68k |
---|---|
Shares outstanding | 188.84m |
Free float | 120.56m |
P/E (TTM) | -- |
Market cap | 406.02m CHF |
EPS (TTM) | -2.11 CHF |
Data delayed at least 15 minutes, as of Apr 17 2024 16:31 BST.
More ▼